Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with
unresectable, stage III non–small-cell lung cancer and no disease progression after …

Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Background Chemoradiotherapy is the standard of care for unresected locally advanced
squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab …

Background Neoadjuvant or adjuvant immunotherapy can improve outcomes in patients
with resectable non–small-cell lung cancer (NSCLC). Perioperative regimens may combine …

Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Protein–protein interactions (PPIs) have pivotal roles in life processes. The studies showed
that aberrant PPIs are associated with various diseases, including cancer, infectious …